12:14 PM
 | 
Jun 16, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

J&J starts Phase III of Tremfya in plaque-type psoriasis

MorphoSys AG (Xetra:MOR; Pink:MPSYY) said the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) began the Phase III ECLIPSE trial to compare Tremfya guselkumab (CNTO 1959) to Cosentyx secukinumab for 44 weeks in about 1,040 patients with moderate to severe plaque-type psoriasis.

The primary endpoint of the double-blind, international trial is the proportion of patients achieving a Psoriasis...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >